Gene therapy developer Asklepios BioPharmaceutical (AskBio) has appointed Don Haut to serve as its chief business officer, the same position he held most recently at Sherlock Biosciences. His experience also includes business development roles at Histogenics, The Medicines Company, Smith & Nephew, and 3M (NYSE: [[ticker:MMM]]). Nearly a year ago, Research Triangle Park, NC-based AskBio raised … Continue reading “Sherlock Bio’s Don Haut Joins AskBio as Chief Business Officer”
Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO
Immunomedics (NASDAQ: [[ticker:IMMU]]) has appointed Harout Semerjian to serve as its president and CEO. Semerjian is joining the Morris Plains, NJ-based cancer drug developer from Ipsen, where he is executive vice president and chief commercial officer. His experience also includes positions at Novartis (NYSE: [[ticker:NVS]]). Semerjian will start at Immunomedics on April 16. An FDA … Continue reading “Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO”
Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13
In the Boston biotech hub, much progress has been made advancing digital health, but significant scientific, technological, financial, and regulatory challenges remain. Join us May 13, 2020 for our Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health interactive online event to learn the latest trends, and network with leading entrepreneurs, scientists, and investors. Agenda includes expert … Continue reading “Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13”
Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test
Millendo Therapeutics is considering a corporate reorganization after its lead drug, an investigational treatment for a rare genetic condition characterized by unrelenting hunger, did not perform better than a placebo in a pivotal trial. The Ann Arbor, MI-based company said Monday that the drug, livoletide, did not meet the goal of the Phase 2b study … Continue reading “Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test”
Menlo’s Itching Drug Racks Up Two More Trial Failures, Program Ends
An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on further development of the compound. The Menlo (NASDAQ: [[ticker:MNLO]]) drug, serlopitant, was being tested in two Phase 3 clinical trials as a treatment for the itching associated with … Continue reading “Menlo’s Itching Drug Racks Up Two More Trial Failures, Program Ends”
Seres Therapeutics Taps Alkermes’s von Moltke as Chief Medical Officer
Seres Therapeutics (NASDAQ: [[ticker:MCRB]]) has appointed Lisa von Moltke to serve as its executive vice president and chief medical officer. She is joining the Cambridge, MA-based microbiome drug developer from Alkermes (NASDAQ: [[ticker:ALKS]]), where she was senior vice president and head of clinical development. Her experience also includes positions at Sanofi (NYSE: [[ticker:SNY]]) and Takeda … Continue reading “Seres Therapeutics Taps Alkermes’s von Moltke as Chief Medical Officer”
GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months
GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental therapies to clinical testing this summer. The partnership will leverage antibody technology from Vir (NASDAQ: [[ticker:VIR]]) and genomics expertise from GSK (NYSE: [[ticker:GSK]]). The companies will work together … Continue reading “GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months”
Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment
Based on the latest news and analysis, as well as conversations from industry experts during the Combatting Coronavirus live panel at BIO-Europe Spring®, Xconomy’s free special report delivers the latest COVID-19 news from the frontlines as top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the current … Continue reading “Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment”
Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic
Last month French biotech Dynacure dosed the first patient in an early-stage trial of its lead drug candidate, a treatment for a group of rare genetic muscle disorders. Now the company, which also has an office in Philadelphia, has landed a €50 million ($55 million) Series C financing round to move that investigational antisense medicine, … Continue reading “Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic”
Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies
Fate Therapeutics has signed an agreement with Janssen Biotech to develop new cancer cell therapies that are derived from stem cells and landed $100 million up front as part of the global collaboration deal. The San Diego-based biotech has built a pipeline of experimental cell therapies that use induced pluripotent stem cells (iPSCs) to create … Continue reading “Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies”
Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials
The global economic crash means the window for initial public stock offerings is all but closed but that didn’t stop Zentalis Phamaceuticals from pushing through. The clinical-stage drug developer priced its IPO late Thursday, raising $165.2 million in its stock market debut. Zentalis was able to sell more shares than it expected, and at a … Continue reading “Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials”
Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More
The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion. ARCH Venture Partners led the pack, adding two funds totaling $1.46 billion to its war chest. Flagship Pioneering bagged $1.1 billion, and venBio Partners reeled in $394 million. Flagship CEO Noubar … Continue reading “Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More”
VenBio Partners Bags $394M to Back More Medicine-Making Biotechs
Investors worried about a recession like venBio Partners’ risk-mitigated approach to venture capital investing. That approach has led new limited partners to join earlier backers in putting nearly $400 million into the San Francisco-based firm’s new fund. VenBio announced Friday it closed its third fund, raising $394 million which it plans to invest using the … Continue reading “VenBio Partners Bags $394M to Back More Medicine-Making Biotechs”
Locana Adds Assembly Biosciences’ Mackison as Chief Business Officer
Locana has appointed Micah Mackison as its chief business officer to lead business development and corporate communications. Mackison most recently led business development efforts at Assembly Biosciences (NASDAQ: [[ticker:ASMB]]) as senior vice president, corporate development and strategy. Previously he led healthcare transactions at Jabil as senior director, corporate investment, and served as head of corporate … Continue reading “Locana Adds Assembly Biosciences’ Mackison as Chief Business Officer”
Flagship Adds $1.1B for New Meds, More AI, & “Health Security”
Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall. One proved eerily prescient: The notion of “health security,” or the development of new products and therapies to treat … Continue reading “Flagship Adds $1.1B for New Meds, More AI, & “Health Security””
BioCryst Pharma Appoints Anthony Doyle Chief Financial Officer
Anthony Doyle has been named chief financial officer of BioCryst Pharmaceuticals (NASDAQ: [[ticker:BCRX]]). He is joining the Durham, NC, rare disease drug developer from Worldwide Clinical Trials, where he has been CFO since 2014. His experience also includes several roles at General Electric (NYSE: [[ticker:GE]]). BioCryst is awaiting an FDA decision for berotralstat, a treatment … Continue reading “BioCryst Pharma Appoints Anthony Doyle Chief Financial Officer”
Brainstorm Cell Therapeutics Names Setboun Chief Operating Officer
David Setboun has been appointed executive vice president and chief operating officer of Brainstorm Cell Therapeutics (NASDAQ: [[ticker:BCLI]]). He is joining New York-based Brainstorm from Life Biosciences, where he was vice president of corporate development, strategy and business. Setboun’s experience also includes positions at Biogen (NASDAQ: [[ticker:BIIB]]), AstraZeneca (NYSE: [[ticker:AZN]]), and Eli Lilly (NYSE: [[ticker:LLY]]). … Continue reading “Brainstorm Cell Therapeutics Names Setboun Chief Operating Officer”
Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID
Celularity, a New Jersey company developing experimental cancer treatments derived from human placentas, has received the FDA’s blessing to kick off human testing of its lead immunotherapy for cases of COVID-19 disease. The trial, designed to evaluate Celularity drug candidate CYNK-001, will enroll about 100 patients with COVID-19 infection causing pneumonia. Those enrolled will receive … Continue reading “Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID”
Iteos Therapeutics Adds $125M to Advance Next-Gen Immunotherapies
Immunotherapies called checkpoint inhibitors have helped change the way a number of cancers are treated by blocking a tumor cell’s ability to hide from the immune system. Some patients don’t respond, however, or develop resistance to these drugs. Iteos Therapeutics has raised $125 million to advance new cancer treatments it is developing to target two … Continue reading “Iteos Therapeutics Adds $125M to Advance Next-Gen Immunotherapies”
Vir Advances Antibodies Against COVID-19, CEO Leads BIO’s Coronavirus Outreach
Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches while working with BIO to facilitate coronavirus collaborations. George Scangos made a surprising shift when the former Biogen CEO left the world of big biotech to lead an infectious disease-focused start-up. Vir … Continue reading “Vir Advances Antibodies Against COVID-19, CEO Leads BIO’s Coronavirus Outreach”
Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic
Parkinson’s disease patients experience progressive breakdown of their neurons, cells essential to movement and mental function. Aspen Neuroscience, a biotech working to develop a therapy that would reprogram those patients’ own living cells in ways that would allow the cells to reconstruct their damaged neural networks, has raised $70 million in a Series A financing … Continue reading “Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic”
Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic
Pandion Therapeutics emerged in 2018 aiming to reach clinic trials in two years testing its biologic drugs in autoimmune and inflammatory disorders. The company now has $80 million to support a lead program in early-stage testing and a pipeline of potential treatments. Access Biotechnology and Boxer Capital led the Series B round of funding announced … Continue reading “Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic”
Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO
Hunter Smith, chief financial officer of Rhythm Pharmaceuticals (NASDAQ: [[ticker:RYTM]]), has been appointed interim CEO. He takes the place of Keith Gottesdiener, who announced in January that he planned to leave his executive positions and the board of directors after Rhythm submitted a new drug application for setmelanotide. The application was filed with the FDA … Continue reading “Rhythm Pharma Files Drug Application, Names Hunter Smith Interim CEO”
Aptinyx Moves Ahead With PTSD Therapy Study, Pauses 3 Other Trials
Neurological drug developer Aptinyx has stopped enrollment in three of the four mid-stage trials it is conducting due to impacts from the coronavirus pandemic. The Evanston, IL-based company disclosed the decision Monday in its report of fourth quarter and full year 2019 financial results. Aptinyx (NASDAQ: [[ticker:APTX]]), which is advancing three clinical-stage drug candidates that … Continue reading “Aptinyx Moves Ahead With PTSD Therapy Study, Pauses 3 Other Trials”
A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy
[Updated 4/10/2020, 3:24 p.m. See below.] Cameron Hewitt’s family celebrates the anniversary of her life not once, but twice yearly: Besides her September birthday, they commemorate a day in March—the anniversary of two-year-old Cameron receiving the gene therapy that gave her a new shot at life. Cameron was born with spinal muscular atrophy (SMA), a … Continue reading “A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy”
Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus
Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare research is funded to focus on early detection and curing rather than managing diseases. “When you look at the investment in research in the pharma industry, it’s all designed to treat established diseases,” William Hait, global head … Continue reading “Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus”
Viracta Adds Nordic Nanovector’s Lisa Rojkjaer as Chief Medical Officer
Viracta Therapeutics has appointed Lisa Rojkjaer as its chief medical officer to oversee the clinical-stage precision oncology company’s efforts to advance treatments targeting virus-associated cancers. Rojkjaer, who will start with the company on May 1, most recently served in the same role at Nordic Nanovector, a precision oncology company in Oslo, Norway. Previously she held … Continue reading “Viracta Adds Nordic Nanovector’s Lisa Rojkjaer as Chief Medical Officer”
Gilead’s Okazaki Named Assembly Bio Chief Legal and Business Officer
Assembly Biosciences (NASDAQ: [[ticker:ASMB]]) is adding another Gilead Sciences (NASDAQ: [[ticker:GILD]]) veteran to its executive team. Jason Okazaki is joining Assembly as its chief legal and business officer. He comes to South San Francisco-based Assembly after 14 years at Gilead, most recently as senior vice president, legal and assistant secretary. Okazaki follows John McHutchinson, the former … Continue reading “Gilead’s Okazaki Named Assembly Bio Chief Legal and Business Officer”
Bioventus CEO Tony Bihl to Retire, Ken Reali Appointed Successor
Bioventus has announced that CEO Tony Bihl will retire on April 30. The Durham, NC-based company has appointed Ken Reali as his successor. He will also join the privately held firm’s board of managers starting on April 20. Reali is coming to Bioventus from Utah-based Clinical Innovations, where he is president and CEO. His experience … Continue reading “Bioventus CEO Tony Bihl to Retire, Ken Reali Appointed Successor”
Biohaven’s Acute Migraine Drug Bests Placebo in Prevention Study
Biohaven Pharmaceutical’s FDA-approved pill to treat migraine attacks is showing that it can prevent such headaches too. According to preliminary results from a late-stage trial released Monday, the Biohaven drug beat a placebo at reducing the average number of days per month patients with chronic and episodic migraine experienced the debilitating condition. The FDA OK’d … Continue reading “Biohaven’s Acute Migraine Drug Bests Placebo in Prevention Study”
Axsome Plans to Try Again After Failure in Treatment-Resistant Depression
An experimental Axsome Therapeutics drug for treatment-resistant depression has fallen short of the main goal of a late-stage test. But the company says the pill is showing enough promise to warrant trying another Phase 3 study. Axsome (NASDAQ: [[ticker:AXSM]]) tested its drug, AXS-05, in patients with major depressive disorder who had previously failed to respond … Continue reading “Axsome Plans to Try Again After Failure in Treatment-Resistant Depression”
San Diego Biotech Entrepreneurs, Innovation Lead to “Maturing” Ecosystem
The local biotech ecosystem is growing up thanks to its innovative science and collaborative ecosystem, advantages that put it nearly on par with the nation’s top life science regions, according to industry veterans. San Diego has long been considered a second-tier primary biopharma hub in terms of number of companies and venture capital raised, falling … Continue reading “San Diego Biotech Entrepreneurs, Innovation Lead to “Maturing” Ecosystem”
Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance
Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one. Sanofi (NYSE: [[ticker:SNY]]) announced Friday that it will develop COVID-19 vaccine candidates with Translate Bio (NASDAQ: [[ticker:TBIO]]), … Continue reading “Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance”
Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others
Equillium has halted two clinical trials of its lead drug candidate out of an “abundance of caution” related to the coronavirus outbreak but continues to enroll in a third, which is evaluating the antibody as a treatment for acute graft-versus-host disease. The decision made by the San Diego biotech, revealed in its annual report filed … Continue reading “Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others”
Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible. Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. Eli Lilly (NYSE: [[ticker:LLY]]) said that … Continue reading “Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More”
Fusion Pharmaceuticals Taps James O’Leary as Chief Medical Officer
Fusion Pharmaceuticals has appointed James O’Leary as its chief medical officer. O’Leary’s experience includes roles at ImmunoGen (NASDAQ: [[ticker:IMGN]]), Idera Pharmaceuticals (NASDAQ: [[ticker:IDRA]]), Array Biopharma, and Deciphera (NASDAQ: [[ticker:DCPH]]), Takeda (NYSE: [[ticker:TAK]]), Bayer, and Pfizer (NYSE: [[ticker:PFE]]). Most recently O’Leary was a global project team leader for a late-stage asset directing global strategy and regulatory … Continue reading “Fusion Pharmaceuticals Taps James O’Leary as Chief Medical Officer”
Akcea Therapeutics Promotes Damien McDevitt to CEO
Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) has appointed Damien McDevitt as its chief executive officer. McDevitt had been serving as the Boston company’s interim CEO since September 2019, when CEO Paula Soteropoulos, president Sarah Boyce, and chief operating officer Jeff Goldberg left in a sudden management shakeup. Akcea is advancing a group of experimental rare disease drugs discovered by … Continue reading “Akcea Therapeutics Promotes Damien McDevitt to CEO”
Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections
Forge Therapeutics has reached a deal with Roche to support development of an antibiotic for drug-resistant bacterial lung infections. The partnership announced this week gives the Swiss pharmaceutical giant the option to license the antibiotic from San Diego-based Forge. The preclinical biotech will retain control of the program, FG-LpxC LUNG, until Roche decides whether to … Continue reading “Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections”
With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases
Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year two investigational treatments that use types of RNA to tweak mutated proteins. Dallas company ReCode Therapeutics and Menlo Park, CA-based TranscripTx have merged under the ReCode name and leadership of CEO … Continue reading “With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases”
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
A multiple sclerosis drug that came to Bristol Myers Squibb via its acquisition of Celgene last year was approved Thursday but don’t expect it to reach patients any time soon. The company says the drug’s launch will be delayed due to the coronavirus pandemic. The Bristol (NYSE: [[ticker:BMY]]) drug, ozanimod (Zeposia), is one of the … Continue reading “FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch”
Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade” recorded for the BIO-Europe Spring partnering conference. The event is produced by EBD Group, … Continue reading “Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel”
Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments
Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year. The Waltham, MA-based company is developing treatments to address the underlying cause of peripheral neuropathies—a form of nerve … Continue reading “Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments”
AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics
After years of research, technology for silencing a gene—stopping it from producing a disease-causing protein—has reached patients. AstraZeneca is now angling for a position in this burgeoning field through an alliance with Silence Therapeutics, a biotech developing such gene-silencing drugs. According to deal terms announced Wednesday, AstraZeneca (NYSE: [[ticker:AZN]]) will pay London-based Silence (LON: [[ticker:SLN]]) … Continue reading “AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics”
Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic
Kallyope, one of New York’s best funded biotechs, has secured more than $100 million to move two of its programs into the clinic—including its most advanced, an experimental drug designed to treat obesity. The company was founded in 2015 with $44 million to leverage new learnings about the “gut-brain axis”—pings of communication between our guts … Continue reading “Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic”
Chrono Therapeutics Top Executive David Happel Joins Cognoa as CEO
David Happel has been appointed CEO of digital therapeutics developer Cognoa. Brent Vaughan, Cognoa’s co-founder and former CEO, will move into a role at venture capital firm Morningside Group, the Palo Alto, CA-based startup’s largest investor. He will also continue to advise Cognoa. Happel joins the company from Chrono Therapeutics, a digital health startup that … Continue reading “Chrono Therapeutics Top Executive David Happel Joins Cognoa as CEO”
CytomX Taps Ex-Alder Bio Exec Campoy as Chief Financial Officer
CytomX Therapeutics has appointed Carlos Campoy to serve as its chief financial officer, the same position he held most recently at Alder BioPharmaceuticals, which was acquired by Lundbeck last year. Campoy’s experience also includes positions at Allergan (NYSE: [[ticker:AGN]]) and Eli Lilly (NYSE: [[ticker:LLY]]). South San Francisco-based CytomX develops antibody cancer drugs. This week, the … Continue reading “CytomX Taps Ex-Alder Bio Exec Campoy as Chief Financial Officer”
CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas
CytomX Therapeutics is teaming up with Astellas Pharma in a research and development alliance focused on developing new cancer immunotherapies based on its antibody technology. Under deal terms announced late Monday, Astellas is paying CytomX (NASDAQ: [[ticker:CTMX]]) $80 million up front. South San Francisco-based CytomX will conduct and finance the research up to the selection … Continue reading “CytomX Lands $80M to Kick Off Cancer Drug R&D Pact With Astellas”
Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing
Aimmune Therapeutics Inc. is navigating a host of new challenges as it launches Palforzia, the first peanut allergy immunotherapy to be approved by the US Food and Drug Administration. Most notably, it must get physician practices and individual allergists certified to administer the treatment. Aimmune (NASDAQ: AIMT) president and CEO Jayson Dallas talked to our sister … Continue reading “Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing”
Genprex Adds Chief Strategy Officer, Chief Operating Officer to C-Suite
Gene therapy company Genprex (NASDAQ: [[ticker:GNPX]]) has added two new executives to its management team: Catherine Vaczy as chief strategy officer and Michael Redman as chief operating officer. Both are executive vice presidents. Vaczy most recently provided strategic advisory services to early stage biotechnology companies. Previously she co-founded and served for a decade on the … Continue reading “Genprex Adds Chief Strategy Officer, Chief Operating Officer to C-Suite”
Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer
Epizyme (NASDAQ: [[ticker:EPZM]]) has appointed Jeffery Kutok as its chief scientific officer to guide the Cambridge, MA-based company’s scientific strategy following the FDA’s approval earlier this year of its first drug as a treatment for epithelioid sarcoma. Kutok was most recently executive vice president and chief scientific officer at Infinity Pharmaceuticals (NASDAQ: [[ticker:INFI]]), which is also based in … Continue reading “Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer”